Direct-to-Consumer (DTC) genome-wide disease risk profiling is currently available to individuals and provides information about one's genetic risk for a range of common polygenic diseases. The Scripps Genomic Health Initiative (SGHI) was launched in 2008 with the aim of evaluating the psychological, behavioral, and clinical impacts of DTC genomic testing on consumers. In a recently published study of over 2,000 individuals who underwent genomic profiling with the Navigenics Health Compass, we found minimal psychological, behavioral, or clinical impacts of testing at short-term follow-up. In this presentation, we will discuss new data based on long-term follow-up of the same group of consumers, as well as analyses evaluating the impact of disease risk testing for relevant subgroups of individuals, including those with or without a family history of disease. Preliminary data on the impact of DTC pharmacogenomic testing, as well as genetic ancestry testing will also be presented. Finally, new directions for research in this area will be discussed.